NBIX - Neurocrine Biosciences, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
San Diego,
United States
Type: Equity
NBIX price evolution
NBIX
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $251.1 | $293.7 | $160.2 | $103.8 |
| Short term investments | $780.5 | $801.4 | $816.5 | $790.8 |
| Net receivables | $439.3 | $417.8 | $387.6 | $391.6 |
| Inventory | $38.3 | $28.8 | $31.7 | $33.4 |
| Total current assets | $1607 | $1649.9 | $1496.6 | $1432.8 |
| Long term investments | $849.4 | $587.5 | $515.6 | $380.3 |
| Property, plant & equipment | $347.3 | $149.6 | $149.1 | $147.2 |
| Goodwill & intangible assets | $35.5 | $34.9 | $36.9 | $37.2 |
| Total noncurrent assets | $1644.4 | $1198.3 | $1116.5 | $927 |
| Total investments | $1629.9 | $1388.9 | $1332.1 | $1171.1 |
| Total assets | $3251.4 | $2848.2 | $2613.1 | $2359.8 |
| Current liabilities | ||||
| Accounts payable | $448.8 | $503 | $391.6 | $355.7 |
| Deferred revenue | ||||
| Short long term debt | $170.1 | $169.9 | $169.7 | |
| Total current liabilities | $654.8 | $691.6 | $582.5 | $374.1 |
| Long term debt | $258.3 | $85.9 | $89.1 | $259.9 |
| Total noncurrent liabilities | $364.6 | $154.5 | $177.6 | $301.2 |
| Total debt | $428.4 | $255.8 | $258.8 | $259.9 |
| Total liabilities | $1019.4 | $846.1 | $760.1 | $675.3 |
| Shareholders' equity | ||||
| Retained earnings | -$157.1 | -$304.8 | -$387.9 | -$483.4 |
| Other shareholder equity | $7 | -$1.7 | -$1.1 | -$2.7 |
| Total shareholder equity | $2232 | $2002.1 | $1853 | $1684.5 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $251.1 | $262.9 | $340.8 | $190.3 |
| Short term investments | $780.5 | $726.4 | $370.5 | $613.9 |
| Net receivables | $439.3 | $350 | $185.5 | $157.1 |
| Inventory | $38.3 | $35.1 | $30.5 | $28 |
| Total current assets | $1607 | $1453.5 | $972.8 | $1016.2 |
| Long term investments | $849.4 | $401.5 | $624.4 | $265.3 |
| Property, plant & equipment | $347.3 | $145.6 | $155.8 | $127.4 |
| Goodwill & intangible assets | $35.5 | $37.2 | ||
| Total noncurrent assets | $1644.4 | $915.2 | $1099.7 | $718.5 |
| Total investments | $1629.9 | $1127.9 | $994.9 | $879.2 |
| Total assets | $3251.4 | $2368.7 | $2072.5 | $1734.7 |
| Current liabilities | ||||
| Accounts payable | $448.8 | $235.7 | $225.8 | $168.7 |
| Deferred revenue | ||||
| Short long term debt | $170.1 | $169.4 | ||
| Total current liabilities | $654.8 | $537.7 | $245.8 | $186.5 |
| Long term debt | $258.3 | $93.5 | $440.4 | $412.3 |
| Total noncurrent liabilities | $364.6 | $123.2 | $452.7 | $422 |
| Total debt | $428.4 | $262.9 | $440.4 | $412.3 |
| Total liabilities | $1019.4 | $660.9 | $698.5 | $608.5 |
| Shareholders' equity | ||||
| Retained earnings | -$157.1 | -$406.8 | -$635.8 | -$725.4 |
| Other shareholder equity | $7 | -$7.9 | -$1.7 | $1.8 |
| Total shareholder equity | $2232 | $1707.8 | $1374 | $1126.2 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $515.2 | $498.8 | $452.7 | $420.4 |
| Cost of revenue | $8.5 | $11.2 | $11.5 | $8.5 |
| Gross Profit | $506.7 | $487.6 | $441.2 | $411.9 |
| Operating activities | ||||
| Research & development | $137.5 | $142.2 | $145.8 | $139.5 |
| Selling, general & administrative | $218.9 | $204.2 | $221.8 | $242.7 |
| Total operating expenses | $356.4 | $346.4 | $367.6 | $526.1 |
| Operating income | $150.3 | $141.2 | $73.6 | -$114.2 |
| Income from continuing operations | ||||
| EBIT | $199.3 | $116.7 | $122.9 | -$102.2 |
| Income tax expense | $50.5 | $32.5 | $26.1 | -$26.7 |
| Interest expense | $1.1 | $1.1 | $1.3 | $1.1 |
| Net income | ||||
| Net income | $147.7 | $83.1 | $95.5 | -$76.6 |
| Income (for common shares) | $147.7 | $83.1 | $95.5 | -$76.6 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1887.1 | $1488.7 | $1133.5 | $1045.9 |
| Cost of revenue | $39.7 | $23.2 | $14.3 | $10.1 |
| Gross Profit | $1847.4 | $1465.5 | $1119.2 | $1035.8 |
| Operating activities | ||||
| Research & development | $565 | $463.8 | $328.1 | $275 |
| Selling, general & administrative | $887.6 | $752.7 | $583.3 | $433.3 |
| Total operating expenses | $1596.5 | $1216.5 | $1016.7 | $872.8 |
| Operating income | $250.9 | $249 | $102.5 | $163 |
| Income from continuing operations | ||||
| EBIT | $336.7 | $221 | $127.2 | $139.5 |
| Income tax expense | $82.4 | $59.4 | $11.8 | -$300.6 |
| Interest expense | $4.6 | $7.1 | $25.8 | $32.8 |
| Net income | ||||
| Net income | $249.7 | $154.5 | $89.6 | $407.3 |
| Income (for common shares) | $249.7 | $154.5 | $89.6 | $407.3 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $147.7 | $83.1 | $95.5 | -$76.6 |
| Operating activities | ||||
| Depreciation | $5.7 | $5.5 | $5.1 | $5 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $38.1 | $47.8 | $68.5 | $39.9 |
| Total cash flows from operations | $123.5 | $212 | $179.6 | -$125.2 |
| Investing activities | ||||
| Capital expenditures | -$5.4 | -$7.6 | -$6.8 | -$8.5 |
| Investments | -$196.4 | -$89.7 | -$119.1 | -$33.6 |
| Total cash flows from investing | -$201.8 | -$97.3 | -$125.9 | -$42.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $35.4 | $18.8 | $2.9 | $8.2 |
| Net borrowings | ||||
| Total cash flows from financing | $35.4 | $18.8 | $2.9 | $8.2 |
| Effect of exchange rate | $0.3 | |||
| Change in cash and equivalents | -$42.6 | $133.5 | $56.6 | -$159.1 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $249.7 | $154.5 | $89.6 | $407.3 |
| Operating activities | ||||
| Depreciation | $21.3 | $15.6 | $10.9 | $8.6 |
| Business acquisitions & disposals | -$42.7 | |||
| Stock-based compensation | $194.3 | $173.1 | $134.2 | $100 |
| Total cash flows from operations | $389.9 | $339.4 | $256.5 | $228.5 |
| Investing activities | ||||
| Capital expenditures | -$28.3 | -$16.5 | -$23.4 | -$10.9 |
| Investments | -$438.8 | -$117.9 | -$106.8 | $15 |
| Total cash flows from investing | -$467.1 | -$177.1 | -$130.2 | $4.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $65.3 | $44.7 | $27.5 | $29.1 |
| Net borrowings | -$279 | -$0.1 | -$186.9 | |
| Total cash flows from financing | $65.3 | -$234.3 | $27.4 | -$157.8 |
| Effect of exchange rate | $0.3 | -$1.3 | ||
| Change in cash and equivalents | -$11.6 | -$73.3 | $153.7 | $74.8 |
News
Fundamentals
| Market cap | $13.09B |
|---|---|
| Enterprise value | $13.27B |
| Shares outstanding | 98.25M |
| Revenue | $1.89B |
|---|---|
| EBITDA | $358.00M |
| EBIT | $336.70M |
| Net Income | $249.70M |
| Revenue Q/Q | 25.05% |
| Revenue Y/Y | 26.76% |
| P/E ratio | 52.42 |
|---|---|
| EV/Sales | 7.03 |
| EV/EBITDA | 37.06 |
| EV/EBIT | 39.40 |
| P/S ratio | 6.94 |
| P/B ratio | 5.88 |
| Book/Share | 22.65 |
| Cash/Share | 2.56 |
| EPS | $2.54 |
|---|---|
| ROA | 9.02% |
| ROE | 12.85% |
| Debt/Equity | 0.46 |
|---|---|
| Net debt/EBITDA | 2.15 |
| Current ratio | 2.45 |
| Quick ratio | 2.40 |